The enhanced metabolic efficiency also supports better energy balance, making it easier to maintain weight loss results long-term
Unlike GLP-1 agonists, 5-amino-1mq does not work through appetite suppression
Reported Research Benefits Used in preclinical research focused on obesity, metabolic syndrome, diabetes, aging-related metabolic decline, fat mass reduction, and muscle preservation during caloric deficit
Some sources suggest the compound is well-absorbed orally based on rat pharmacokinetic data, while others argue that subcutaneous injection provides more reliable absorption
Summary: Retatrutide and 5-Amino-1MQ are both unlicensed compounds in the UK retatrutide is an investigational triple incretin receptor agonist in clinical trials, whilst 5-Amino-1MQ is a research chemical with no approved human therapeutic use
Insulin Syringes (U-100) One fresh syringe per injection